Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Bolivia’s Ex-President Luis Arce Detained in Embezzlement Probe 
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
